NCT05626400View on ClinicalTrials.gov

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

NARecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

October 30, 2027

Study Completion Date

December 30, 2027

Conditions

T-cell Acute Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL

Senl-T7

Patients will be treated with CD7 CAR-T cells

Trial Locations (1)

Unknown

RECRUITING

Hebei yanda Hospital, Beijingcun

All Listed Sponsors

lead

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

NCT05626400 - Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL | Biotech Hunter | Biotech Hunter